Alzheimer's Disease - HealthQuill

Scientists have discovered five known cases of possible medically acquired Alzheimer’s disease after the patients have undergone previous treatments.

Researchers find five cases of medically-acquired Alzheimer’s in UK

HQ Team February 12, 2024: Scientists have discovered five known cases of possible medically acquired Alzheimer’s disease after the patients have undergone previous.

by HealthQuill
February 12, 2024
0 Comments

Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed to rope in a partner to cut costs of obtaining standard regulatory approval.

Drugs Health Pharma

Biogen abandons Alzheimer’s drug Aduhelm to focus on Leqembi

Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed.

by HealthQuill
February 1, 2024
0 Comments

AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to boost the North Chicago, Illinois-based company’s presence in the psychiatric and neurological disorder segment.

Drugs Health Pharma

AbbVie to acquire Cerevel for $8.7b to bolster neurological treatments

HQ Team December 7, 2023: AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to.

by HealthQuill
December 7, 2023
0 Comments

Experiments conducted on young adult rats have established a link between Alzheimer’s and gut microbiota, according to a global study.

Drugs Health Pharma

Scientists connect gut microbiota to Alzheimer’s disease in lab experiments

HQ Team October 19, 2023: Experiments conducted on young adult rats have established a link between Alzheimer’s and gut microbiota, according to a.

by HealthQuill
October 19, 2023
2 Comments

Researchers at Sweden’s Lund University have identified a new biomarker to detect Parkinson’s disease before a person develops symptoms.

Drugs Health Pharma

Swedish researchers identify new biomarker to detect Parkinson’s disease

HQ Team September 26, 2023: Researchers at Sweden’s Lund University have identified a new biomarker to detect Parkinson’s disease before a person develops.

by HealthQuill
September 26, 2023
0 Comments

Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for detecting Alzheimer’s disease early.

Drugs Health Pharma

Quest Diagnostics unveils direct-to-customer tests for Alzheimer’s

HQ Team August 1, 2023: Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for.

by HealthQuill
August 1, 2023
0 Comments

Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of the disease, according to a company statement.

Drugs Health Pharma

Eli Lilly: Alzheimer’s test drug slows cognitive decline in early stages

HQ Team July 18, 2023: Eli Lilly’s Alzheimer’s experimental drug, donanedab, slowed down cognitive and functional decline in people with early symptoms of.

by HealthQuill
July 18, 2023
0 Comments

The USFDA has granted a standard approval for Eisai and Biogen's Alzheimer injection, Leqembi —the first treatment to secure the traditional approval, paving the way for wider insurance coverage of the drug.

Drugs Health Pharma

USFDA grants green light to Eisai, Biogen’s Alzheimer’s drug Leqembi

HQ Team July 7, 2023: The USFDA has granted a standard approval for Eisai and Biogen’s Alzheimer injection, Leqembi —the first treatment to secure the.

by HealthQuill
July 7, 2023
0 Comments

A blood protein, called fibrin, which supports clotting, is responsible for switching on detrimental genes in Alzheimer’s disease and multiple sclerosis, researchers say.

Drugs Health Pharma

Alzheimer’s develops when hero microglia turns into a villain in brain

HQ Team June 11, 2023: A blood protein, called fibrin, which supports clotting, is responsible for switching on detrimental genes in Alzheimer’s disease.